36 results
8-K
EX-99.2
GOSS
Gossamer Bio Inc
14 May 19
Gossamer Bio Announces First Quarter 2019 Financial Results
7:31am
; Farne, Expert Opinion on Emerging Drugs 2016; Stone, J Allergy Clin Immunol 2010; Saunders, Sci Transl. Med. 2019. PGD2 DP2 PGD2 TH2 DP2 PGD2 ILC2 IL-13
DEF 14A
GOSS
Gossamer Bio Inc
30 Apr 19
Definitive proxy
4:04pm
determined that Ms. Galá is an “audit committee financial expert” as defined by applicable SEC rules and has the requisite financial sophistication … it provide any expert assurance or professional certification regarding the company’s financial statements. The audit committee relies, without independent
S-1
EX-10.14
c9goj3 yi0xkyf
21 Dec 18
IPO registration
4:39pm
PRE 14A
fi829qf0z0k
17 Apr 23
Preliminary proxy
4:01pm
S-1
EX-10.10
v6gdi3 su17r16
21 Dec 18
IPO registration
4:39pm
S-1
EX-10.13
c2jdj8 hn1infua5
21 Dec 18
IPO registration
4:39pm
S-1
EX-10.11
k0rkpe w8vu0jiez8d2
21 Dec 18
IPO registration
4:39pm
S-1
EX-10.9
5hadc5cm4u
21 Dec 18
IPO registration
4:39pm